TG40 Stock Overview
A biopharmaceutical company, develops medicines to prevent blindness.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Oxurion NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.39 |
| 52 Week High | €53.00 |
| 52 Week Low | €0.39 |
| Beta | 0.58 |
| 11 Month Change | -60.60% |
| 3 Month Change | -60.60% |
| 1 Year Change | -93.43% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| TG40 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -21.5% | 2.6% | 4.5% |
| 1Y | -93.4% | -16.4% | 13.4% |
Return vs Industry: TG40 underperformed the German Biotechs industry which returned -16.4% over the past year.
Return vs Market: TG40 underperformed the German Market which returned 13.4% over the past year.
Price Volatility
| TG40 volatility | |
|---|---|
| TG40 Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TG40's share price has been volatile over the past 3 months.
Volatility Over Time: TG40's weekly volatility has decreased from 140% to 10% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 20 | Pascal Ghoson | www.oxurion.com |
Oxurion NV, a biopharmaceutical company, develops medicines to prevent blindness. It focuses on developing ophthalmic treatments to preserve vision for patients with retinal disorders, including geographic atrophy and age-related macular degeneration. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018.
Oxurion NV Fundamentals Summary
| TG40 fundamental statistics | |
|---|---|
| Market cap | €553.21k |
| Earnings (TTM) | -€18.97m |
| Revenue (TTM) | €263.00k |
2.1x
P/S Ratio0.0x
P/E RatioIs TG40 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TG40 income statement (TTM) | |
|---|---|
| Revenue | €263.00k |
| Cost of Revenue | €159.00k |
| Gross Profit | €104.00k |
| Other Expenses | €19.07m |
| Earnings | -€18.97m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.20 |
| Gross Margin | 39.54% |
| Net Profit Margin | -7,212.55% |
| Debt/Equity Ratio | -91.1% |
How did TG40 perform over the long term?
See historical performance and comparison